SCHEMBL81245

SCHEMBL81245

FC(F)(F)c1cccc(CCCBr)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.62
MIF P14174 2/20 0.53
HDAC1 Q13547 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
IDO1 P14902 2/20 0.51
HTR2C P28335 3/20 0.50
HTR2B P41595 3/20 0.50
HTR2A P28223 2/20 0.50
ACP3 P15309 1/20 0.49
CYP2D6 P10635 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
CYP2C19 P33261 1/20 0.48
DAO P14920 2/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GAA P10253 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31543288 1.00 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL16298283 0.93 TAAR1 (0.59) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL7384474 0.93 TAAR1 (0.59) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL177514 0.89 TAAR1 (0.67) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL30186510 0.89 TAAR1 (0.67) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL11383498 0.83 TAAR1 (0.65) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL4664652 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL1723183 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL1046263 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL21913967 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104774134-A Synthetic method of cinacalcet hydrochloride and intermediate compound of cinacalcet hydrochloride Chengdu zihao pharmaceutical co ltd 2015-07-15 CN claimed
US-8969623-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2015-03-03 US claimed
CN-103044267-A Preparation method of high-purity cinacalcet hydrochloride CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD 2013-04-17 CN claimed
EP-2406211-A2 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF Megafine Pharma (P) Ltd. (IN) 2012-01-18 EP claimed
WO-2010103531-A2 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF MEGAFINE PHARMA (P) LTD. (IN) 2010-09-16 WO claimed
CN-120365778-A High-weather-resistance photovoltaic panel coating material and preparation method thereof 斯科瑞新材料科技(山东)股份有限公司 2025-07-25 CN disclosed
WO-2024145659-A1 HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR INTRA-CELLULAR THERAPIES, INC. (US) 2024-07-04 WO disclosed
US-11535647-B2 Peptide purification method using sulfonate compound NAGASE & CO., LTD. (JP) 2022-12-27 US disclosed
CN-112321451-B Method for preparing cinacalcet hydrochloride drug intermediate 福建海西新药创制有限公司 2022-08-23 CN disclosed
US-20220144888-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND NAGASE & CO., LTD. (JP) 2022-05-12 US disclosed
CN-112321451-A Method for preparing cinacalcet hydrochloride drug intermediate 福建海西新药创制有限公司 2021-02-05 CN disclosed
CN-111018734-B Synthesis method of cinacalcet hydrochloride intermediate 福建海西新药创制有限公司 2020-12-22 CN disclosed
CN-101730677-A Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORP 2010-06-09 CN disclosed
EP-2168944-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed
WO-2010010359-A2 A PROCESS FOR THE PREPARATION OF CINACALCET AND ITS SALTS CILPA LIMITED (IN) 2010-01-28 WO disclosed
WO-2008058235-A2 PROCESSES FOR THE PREPARATION OF CINACALCET DR. REDDY'S LABORATORIES, LTD. (IN) 2008-05-15 WO disclosed
WO-2008058236-A2 METHODS FOR PREPARING CINACALCET HYDROCHLORIDE DR. REDDY'S LABORTORIES, LTD. (IN) 2008-05-15 WO disclosed
WO-2006082412-A2 MULTIMERS OF PYRIMIDINONE DERIVATIVES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS ARGENTA DISCOVERY LIMITED (GB) 2006-08-10 WO disclosed
US-5262420-A Phenylalkylpyridines IDEMITSU KOSAN CO., LTD. (JP) 1993-11-16 US disclosed
EP-0383950-A1 PYRIDINE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT IDEMITSU KOSAN COMPANY LIMITED (JP) 1990-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144888-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND VIP, IAPP, RPS27A TAAR1 4329/4885MIF 2589/4885HDAC1 3514/4885
US-11535647-B2 Peptide purification method using sulfonate compound VIP, IAPP, RPS27A TAAR1 4329/4885MIF 2589/4885HDAC1 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.